Publikation
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial
Wissenschaftlicher Artikel/Review - 10.10.2016
Rochlitz Christoph, Rordorf Tamara, Rauch Daniel, Müller Andreas, Ruhstaller Thomas, Vetter Marcus, Trojan Andreas, Hasler-Strub Ursula, Cathomas Richard, Winterhalder Ralph, Borner Markus, Bärtschi Daniela, Bigler Martin, von Moos Roger, Bernhard Jürg, Matter-Walstra Klazien, Wicki Andreas, Zaman Khalil, Anchisi Sandro, Küng Marc, Na Kyung-Jae
Rochlitz, Christoph
13
0
Bigler, Martin
3
0
von Moos, Roger
58
1
Bernhard, Jürg
18
0
Matter-Walstra, Klazien
6
0
Wicki, Andreas
4
0
Zaman, Khalil
8
0
Anchisi, Sandro
5
0
Küng, Marc
1
0
Na, Kyung-Jae
2
0
Bärtschi, Daniela
5
0
Borner, Markus
7
0
Rordorf, Tamara
Leitende(r) Arzt/ÄrztinBrustzentrum St.Gallen, Medizinische Onkologie und Hämatologie · Dept. IV, Dept. I
34
1
Rauch, Daniel
16
0
Müller, Andreas
7
0
Ruhstaller, Thomas
83
24
Vetter, Marcus
1
0
Trojan, Andreas
4
0
Hasler-Strub, Ursula
5
11
Cathomas, Richard
55
1